Erste Group analyst Hans Engel upgraded Novartis to Buy from Hold. The company should achieve sales growth in the low to mid single-digit percentage range in 2023 and a spin-off of the Sandoz generics business that is “likely soon” would further strengthen its profitability, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVS:
- Novartis names AbbVie’s Patrick Horber as President, International
- Novartis sues U.S. government over price regulation, Reuters reports
- Novartis participates in a conference call with Jefferies
- Novartis shares rising but challenges remain, WSJ reports
- Biden unveils first 10 drugs subject to Medicare price negotiation